Shares of Natco Pharma Ltd. gained up to 3% on Friday, October 17, after the Supreme Court dismissed a plea by Roche, challenging the interim Delhi High Court Order on the roll out of the generic version of the Risdipalm.

The Supreme Court, during its hearing said that there is no reason to interfere with the interim order issued by the Delhi High Court and subsequently refused to restrain Natco Pharma from the sale and export of the generic version of the Risdipalm.

The Apex court has also directed that the hearing on the Roche-Natco dispute in the Delhi High Court should be expedited.

With this judgment, Natco Pharma can now sell the Spinal Muscular Atrophy treatment drug for ₹15,900 compared to the previous Roche's imported price of ₹6 lakh, resulting in a big win for patients. The d

See Full Page